Form 4: Exagen CFO Jeffrey Black Boosts Stake with RSU, Options

Exagen's Chief Financial Officer, Jeffrey G. Black, reported significant acquisitions of restricted stock units, stock options, and common stock through an employee plan.

Summary

• Jeffrey G. Black, Chief Financial Officer of Exagen Inc. (XGN), reported multiple acquisitions of company securities.
• On March 12, 2026, Black was awarded 75,000 restricted stock units (RSUs) at a price of $3.16 per unit. These RSUs vest 25% annually over four years, starting from February 21, 2026.
• Also on March 12, 2026, Black acquired 50,000 stock options with an exercise price of $3.16, expiring on March 11, 2036. These options vest 25% on February 21, 2027, and then 1/48th monthly thereafter.
• On February 27, 2026, Black purchased 1,511 shares of common stock through the Employee Stock Purchase Plan (ESPP) at $3.077 per share.
• Following these transactions, Black beneficially owns 342,442 shares of common stock (after the RSU award) and 60,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a key executive is increasing their stake and long-term incentives, indicating confidence in the company's future, which is generally favorable for investors.

Positives

• CFO Jeffrey G. Black increased his direct ownership and incentive-based holdings in Exagen Inc. through RSU awards, stock options, and ESPP purchases.
• The acquisition of 75,000 restricted stock units and 50,000 stock options aligns management's interests with long-term shareholder value through multi-year vesting schedules.
• The purchase of 1,511 shares via the Employee Stock Purchase Plan at $3.077 indicates confidence in the company's valuation by a key executive.

Risks

• The vesting of restricted stock units and stock options is contingent on the Reporting Person's continued service to the Issuer through the applicable vesting dates.
• Full vesting of RSUs and stock options may occur upon a qualifying termination of employment in connection with a change in control, which could accelerate equity awards under specific circumstances.

Future Outlook

The future outlook indicates a long-term commitment from the CFO, with significant equity awards (RSUs and stock options) vesting over several years, contingent on continued service. The vesting schedules extend through February 2030 for RSUs and beyond February 2027 for options, aligning executive incentives with the company's sustained performance.

Management Comments

• The securities awarded are in the form of restricted stock units under the issuer's 2019 Incentive Award Plan.
• The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 21, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
• The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP").
• The option is exercisable as it vests. 25% of the shares subject to the option vest on February 21, 2027, and 1/48th of the total number of shares subject to the option vest at the end of each calendar month thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a Chief Financial Officer, often signals management's confidence in the company's future prospects. The combination of RSU awards, stock options, and ESPP purchases suggests a multi-faceted approach to executive compensation, aiming to retain key talent and align their financial interests with long-term shareholder value, a common practice in the biotechnology and diagnostic industry where long development cycles are prevalent.

Comparison to Industry Standards

• The structure of equity awards, including multi-year vesting for RSUs (25% annually over four years) and stock options (25% after one year, then monthly), is consistent with typical executive compensation packages in the U.S. public market, particularly in growth-oriented sectors like healthcare and diagnostics.
• The inclusion of an Employee Stock Purchase Plan (ESPP) is a standard benefit offered by many publicly traded companies, encouraging broad employee ownership.
• Similar vesting schedules and equity incentive plans are observed at peers such as Guardant Health (GH), Natera (NTRA), and Veracyte (VCYT), which also operate in the diagnostics space and utilize equity to incentivize long-term performance.

Related Party Transactions

• Award of 75,000 restricted stock units to CFO Jeffrey G. Black under the 2019 Incentive Award Plan.
• Award of 50,000 stock options to CFO Jeffrey G. Black with an exercise price of $3.16.
• Purchase of 1,511 common shares by CFO Jeffrey G. Black through the Employee Stock Purchase Plan at $3.077.

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership and long-term incentives can align management's interests with shareholder value creation.
• Employees: The ESPP indicates a broader program for employee ownership, which can boost morale and retention.
• Management: Jeffrey G. Black's compensation package is enhanced with long-term equity, incentivizing his continued performance and commitment to the company.

Next Steps

• Continued service of Jeffrey G. Black to the Issuer for the vesting of RSUs and stock options.
• Future vesting dates for RSUs on the anniversaries of February 21, 2026.
• Future vesting dates for stock options starting February 21, 2027, and monthly thereafter.

Key Dates

Recommendation

The filing details routine executive compensation and an employee stock purchase, which are standard practices and do not present new information that would significantly alter the investment thesis. While insider buying is generally positive, these are primarily incentive awards rather than open-market purchases, suggesting a 'hold' recommendation as the filing does not provide a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Exagen Inc., XGN, Jeffrey G. Black, CFO, Form 4, insider trading, restricted stock units, RSU, stock options, ESPP, employee stock purchase plan, beneficial ownership, executive compensation, equity awards, vesting